|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ABCB6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ABCC4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ABCG2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abhd14a |
abhydrolase domain containing 14A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ABHD14A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ABHD3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840
|
|
G |
Acad11 |
acyl-CoA dehydrogenase family, member 11 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ACAD11 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:112,594,758...112,676,275
Ensembl chr 8:112,594,691...112,676,280
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACADSB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ACTA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ACTC1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ADAM28 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:50,356,745...50,425,911
Ensembl chr15:50,358,192...50,425,900
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ADAMTS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ADAMTS20 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:135,465,021...135,630,941
Ensembl chr 7:135,466,884...135,630,654
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ADCYAP1R1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ADGRG2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:36,930,186...37,054,968
Ensembl chr X:36,930,186...37,003,642
|
|
G |
Ajap1 |
adherens junctions associated protein 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of AJAP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:170,615,885...170,679,315
Ensembl chr 5:170,615,886...170,679,315
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of AKR1C2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of AKR1C3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ALDOC mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDOC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of AMBP mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
Ank1 |
ankyrin 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANK1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:73,681,422...73,912,605
Ensembl chr16:73,681,422...73,827,488
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANKRD1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548
|
|
G |
Ankrd26 |
ankyrin repeat domain 26 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ANKRD26 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD26 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:150,548,656...150,616,928
Ensembl chr 4:150,547,467...150,616,895
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANTXR1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:118,946,267...119,131,202
Ensembl chr 4:118,946,268...119,131,202
|
|
G |
Anxa1 |
annexin A1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANXA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa2 |
annexin A2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANXA2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa3 |
annexin A3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ANXA3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of AOX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Apcdd1 |
APC down-regulated 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of APCDD1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:58,270,398...58,300,982
Ensembl chr18:58,270,410...58,301,002
|
|
G |
Apela |
apelin receptor early endogenous ligand |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of APELA mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:26,582,103...26,583,828
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARAP2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARHGAP15 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219
|
|
G |
Arhgef28 |
Rho guanine nucleotide exchange factor 28 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARHGEF28 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:25,738,514...26,011,429
Ensembl chr 2:25,738,514...26,011,429
|
|
G |
Arhgef40 |
Rho guanine nucleotide exchange factor 40 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARHGEF40 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF40 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:28,377,916...28,403,090
Ensembl chr15:28,377,996...28,403,090
|
|
G |
Arhgef9 |
Cdc42 guanine nucleotide exchange factor 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ARHGEF9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:64,249,576...64,428,444
Ensembl chr X:64,248,278...64,428,592
|
|
G |
Arl10 |
ADP-ribosylation factor like GTPase 10 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ARL10 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:10,567,064...10,575,518
Ensembl chr17:10,568,959...10,575,203
|
|
G |
Arl9 |
ADP-ribosylation factor like GTPase 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ARL9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:33,436,803...33,447,516
Ensembl chr14:33,436,980...33,444,235
|
|
G |
Armh1 |
armadillo-like helical domain containing 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARMH1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARMH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:136,073,056...136,112,344
Ensembl chr 5:136,073,056...136,112,344
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ARMH4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:26,586,359...26,687,412
Ensembl chr15:26,587,179...26,678,420
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ARRB1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arx |
aristaless related homeobox |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ARX mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:62,363,757...62,376,139
Ensembl chr X:62,363,757...62,376,143
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ASF1A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:34,894,419...34,909,265
Ensembl chr20:34,894,419...34,909,265
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ASIC1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ASNS mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Asphd1 |
aspartate beta-hydroxylase domain containing 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ASPHD1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:198,379,060...198,382,982
Ensembl chr 1:198,379,022...198,382,614
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ATF5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atg10 |
autophagy related 10 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ATG10 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATG10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:19,853,546...20,152,918
Ensembl chr 2:19,853,546...20,152,884
|
|
G |
Atl3 |
atlastin GTPase 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ATL3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:222,746,023...222,788,439
Ensembl chr 1:222,746,023...222,786,942
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ATP8A1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ATP8B1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
|
|
G |
Atxn2l |
ataxin 2-like |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATXN2L mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:197,908,087...197,920,400
Ensembl chr 1:197,908,094...197,919,560
|
|
G |
Aurka |
aurora kinase A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of AURKA mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AURKA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
B9d1 |
B9 domain containing 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of B9D1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:47,784,294...47,794,399
Ensembl chr10:47,785,033...47,792,590 Ensembl chr10:47,785,033...47,792,590
|
|
G |
Bag2 |
BAG cochaperone 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BAG2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:38,456,487...38,467,120
Ensembl chr 9:38,456,468...38,467,118
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BAG3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bag5 |
BAG cochaperone 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BAG5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAG5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:136,180,640...136,185,651
Ensembl chr 6:136,182,006...136,185,651
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BAMBI mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
|
|
G |
Bcan |
brevican |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BCAN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:187,359,674...187,373,133
Ensembl chr 2:187,359,677...187,372,657
|
|
G |
Bche |
butyrylcholinesterase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BCHE mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2l11 |
BCL2 like 11 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BCL2L11 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BCL6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bco1 |
beta-carotene oxygenase 1 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BCO1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr19:49,637,059...49,673,577
Ensembl chr19:49,637,016...49,673,808
|
|
G |
Bcor |
BCL6 co-repressor |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BCOR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:11,570,155...11,692,022
Ensembl chr X:11,648,989...11,691,099
|
|
G |
Bend4 |
BEN domain containing 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of BEND4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:42,399,359...42,401,643 NCBI chr14:42,401,665...42,437,957
Ensembl chr14:42,401,706...42,431,480
|
|
G |
Bend6 |
BEN domain containing 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BEND6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:38,297,253...38,351,312
Ensembl chr 9:38,297,322...38,351,024
|
|
G |
Best4 |
bestrophin 4 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:136,013,978...136,017,742
Ensembl chr 5:136,014,017...136,017,677
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BHLHE40 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bik |
BCL2-interacting killer |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BIK mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bloc1s5 |
biogenesis of lysosomal organelles complex 1 subunit 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MUTED mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLOC1S5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:26,808,193...26,833,257
Ensembl chr17:26,808,330...26,833,247
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BLVRB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BMP5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA p-Chloromercuribenzoic Acid results in increased expression of BMP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BTG2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of BTG3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201
|
|
G |
C1s |
complement C1s |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of C1S mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
|
|
G |
Ca13 |
carbonic anhydrase 13 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CA13 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:88,282,961...88,314,254
Ensembl chr 2:88,282,961...88,314,254
|
|
G |
Ca4 |
carbonic anhydrase 4 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CA4 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
|
|
G |
Cabyr |
calcium binding tyrosine phosphorylation regulated |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CABYR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CABYR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:4,082,175...4,096,650
Ensembl chr18:4,084,228...4,095,936
|
|
G |
Cachd1 |
cache domain containing 1 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CACHD1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:119,596,726...119,832,326
Ensembl chr 5:119,727,839...119,831,634
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CACNB2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
|
|
G |
Calb1 |
calbindin 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CALB1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Caln1 |
calneuron 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CALN1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:29,307,117...29,796,996
Ensembl chr12:29,308,341...29,743,705
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CAMK2D mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CAMK2N1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486
|
|
G |
Capn6 |
calpain 6 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CAPN6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr X:115,049,113...115,073,824
Ensembl chr X:115,049,154...115,073,890
|
|
G |
Caps2 |
calcyphosine 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CAPS2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:54,858,841...54,917,406
Ensembl chr 7:54,859,104...54,917,323
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CARS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp3 |
caspase 3 |
decreases activity |
ISO |
p-Chloromercuribenzoic Acid results in decreased activity of CASP3 protein |
CTD |
PMID:26272509 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CASP8 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cav2 |
caveolin 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CAV2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Cbx5 |
chromobox 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CBX5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:144,819,673...144,865,014
Ensembl chr 7:144,819,420...144,837,583
|
|
G |
Cc2d1b |
coiled-coil and C2 domain containing 1B |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CC2D1B mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:128,215,711...128,229,762
Ensembl chr 5:128,215,711...128,229,737
|
|
G |
Ccbe1 |
collagen and calcium binding EGF domains 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCBE1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:61,758,754...62,013,194
Ensembl chr18:61,759,289...61,788,863
|
|
G |
Ccdc121 |
coiled-coil domain containing 121 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCDC121 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:99,819,380...99,821,055
Ensembl chr13:99,820,015...99,820,986
|
|
G |
Ccdc136 |
coiled-coil domain containing 136 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCDC136 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:56,674,737...56,704,501
Ensembl chr 4:56,674,832...56,704,549
|
|
G |
Ccdc177 |
coiled-coil domain containing 177 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCDC177 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:104,403,617...104,410,991
Ensembl chr 6:104,406,897...104,409,005
|
|
G |
Ccdc74a |
coiled-coil domain containing 74A |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCDC74A mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:87,547,026...87,554,513
Ensembl chr11:87,549,059...87,553,336
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CCN2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCNG2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccnt2 |
cyclin T2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CCNT2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739
|
|
G |
Cd82 |
Cd82 molecule |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CD82 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CDC42BPA mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42BPA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CDH1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CDH11 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245
|
|
G |
Cdh6 |
cadherin 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CDH6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:63,100,723...63,246,618
Ensembl chr 2:63,101,739...63,166,509
|
|
G |
Cdh7 |
cadherin 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CDH7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:31,081,064...31,228,884
Ensembl chr13:31,081,804...31,231,213
|
|
G |
Cdh9 |
cadherin 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CDH9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:66,938,796...67,078,897
Ensembl chr 2:66,940,057...67,078,784
|
|
G |
Cdk15 |
cyclin-dependent kinase 15 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CDK15 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:66,059,765...66,153,729
Ensembl chr 9:66,058,047...66,148,087
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CDK6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CDKN1A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CEBPB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cel |
carboxyl ester lipase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CEL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Celf5 |
CUGBP, Elav-like family member 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CELF5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:11,095,449...11,119,941
Ensembl chr 7:11,095,468...11,119,941
|
|
G |
Cep19 |
centrosomal protein 19 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:71,921,713...71,938,335
Ensembl chr11:71,921,716...71,938,165
|
|
G |
Cep83 |
centrosomal protein 83 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CEP83 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP83 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:35,739,553...35,847,618
Ensembl chr 7:35,773,928...35,847,617
|
|
G |
Cep85l |
centrosomal protein 85-like |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CEP85L mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418
|
|
G |
Cfap91 |
cilia and flagella associated protein 91 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CFAP91 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:64,975,499...65,019,169
Ensembl chr11:64,975,594...65,018,108
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CFTR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CHD9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:17,364,969...17,517,757
Ensembl chr19:17,366,828...17,494,585
|
|
G |
Chka |
choline kinase alpha |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CHKA mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220
|
|
G |
Chodl |
chondrolectin |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CHODL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165
|
|
G |
Chrdl1 |
chordin-like 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CHRDL1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:114,554,359...114,658,975
Ensembl chr X:114,554,359...114,658,931
|
|
G |
Cib1 |
calcium and integrin binding 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CIB1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:142,014,962...142,020,461
Ensembl chr 1:142,014,958...142,020,525
|
|
G |
Cln3 |
CLN3 lysosomal/endosomal transmembrane protein, battenin |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CLN3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:197,986,384...197,999,726
Ensembl chr 1:197,986,385...197,997,664
|
|
G |
Clu |
clusterin |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CLU mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cluap1 |
clusterin associated protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLUAP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:11,847,058...11,878,792
Ensembl chr10:11,847,102...11,878,792
|
|
G |
Cnfn |
cornifelin |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CNFN mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:82,234,032...82,236,602
Ensembl chr 1:82,234,032...82,236,179
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CNKSR2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:39,711,001...39,953,860
Ensembl chr X:39,711,201...39,951,847
|
|
G |
Cntn2 |
contactin 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CNTN2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:49,280,913...49,314,061
Ensembl chr13:49,285,310...49,313,940
|
|
G |
Cntnap3 |
contactin associated protein family member 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CNTNAP3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:2,197,355...2,380,727
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of COL1A2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Colgalt2 |
collagen beta(1-O)galactosyltransferase 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of COLGALT2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:69,797,558...69,902,916
Ensembl chr13:69,797,880...69,901,170
|
|
G |
Cpeb2 |
cytoplasmic polyadenylation element binding protein 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CPEB2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:72,327,929...72,382,519
Ensembl chr14:72,331,705...72,380,330
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CPT1A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CREM mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Ctc1 |
CST telomere replication complex component 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CTC1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:55,596,172...55,616,873
Ensembl chr10:55,596,148...55,616,889
|
|
G |
Ctcfl |
CCCTC-binding factor like |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTCFL mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:171,145,203...171,168,375
Ensembl chr 3:171,145,584...171,166,454
|
|
G |
Ctdsp1 |
CTD small phosphatase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CTDSP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:81,672,613...81,677,979
Ensembl chr 9:81,672,758...81,677,979
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CTH mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnd2 |
catenin delta 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CTNND2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Cuzd1 |
CUB and zona pellucida-like domains 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUZD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:201,881,846...201,894,970
Ensembl chr 1:201,881,836...201,894,775
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CXCL12 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CXCL6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CXCR2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of CXCR4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CYP1B1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases activity |
EXP |
p-Chloromercuribenzoic Acid results in decreased activity of CYP7A1 protein |
CTD |
PMID:1175606 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyth3 |
cytohesin 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of CYTH3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:12,877,559...12,907,771
Ensembl chr12:12,877,559...12,945,192
|
|
G |
Dab1 |
DAB adaptor protein 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DAB1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115
|
|
G |
Dbr1 |
debranching RNA lariats 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DBR1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,826,690...107,838,186
Ensembl chr 8:107,826,424...107,838,339
|
|
G |
Dcx |
doublecortin |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DCX mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:115,098,675...115,175,515
Ensembl chr X:115,098,675...115,175,299
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DDIT3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DDIT4L mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:242,882,219...242,885,088
Ensembl chr 2:242,882,306...242,885,131
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DDR2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:88,311,639...88,436,561
Ensembl chr13:88,317,145...88,436,789
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DDX58 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX58 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
|
|
G |
Dennd1b |
DENN domain containing 1B |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DENND1B mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:56,015,813...56,242,041
Ensembl chr13:56,015,901...56,236,677
|
|
G |
Dennd2c |
DENN domain containing 2C |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DENND2C mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:205,592,348...205,660,619
Ensembl chr 2:205,592,182...205,660,611
|
|
G |
Dgki |
diacylglycerol kinase, iota |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DGKI mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473
|
|
G |
Dgkq |
diacylglycerol kinase, theta |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DGKQ mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:2,069,409...2,083,370
Ensembl chr14:2,069,409...2,083,370
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DHRS11 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:72,144,042...72,153,496
Ensembl chr10:72,144,042...72,153,375
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DHRS2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
|
|
G |
Dhx30 |
DExH-box helicase 30 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DHX30 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:118,160,315...118,194,674
Ensembl chr 8:118,160,299...118,187,791
|
|
G |
Dio3os |
DIO3 opposite strand upstream RNA |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DIO3OS mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3OS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:134,623,450...134,626,974
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DLG1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DLL1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dlx3 |
distal-less homeobox 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DLX3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:82,937,971...82,943,367
Ensembl chr10:82,937,971...82,943,348
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DLX5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,387,741...32,392,085
Ensembl chr 4:32,387,741...32,392,007
|
|
G |
Dlx6 |
distal-less homeobox 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DLX6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,373,096...32,377,388
Ensembl chr 4:32,373,641...32,377,253
|
|
G |
Dnah1 |
dynein, axonemal, heavy chain 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DNAH1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:7,345,131...7,407,009
Ensembl chr16:7,345,978...7,408,265
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dock6 |
dedicator of cytokinesis 6 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DOCK6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:22,822,412...22,874,670
Ensembl chr 8:22,822,412...22,874,645
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of DOCK7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:117,595,194...117,780,844
Ensembl chr 5:117,596,136...117,780,777
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DUSP14 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of DUSP5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
|
|
G |
Dusp8 |
dual specificity phosphatase 8 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:215,030,429...215,043,111
Ensembl chr 1:215,030,429...215,033,460
|
|
G |
Ebf1 |
EBF transcription factor 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EBF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EBF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209
|
|
G |
Eef1akmt2 |
EEF1A lysine methyltransferase 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EEF1AKMT2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:204,830,008...204,855,627
Ensembl chr 1:204,831,540...204,855,627
|
|
G |
Eef1akmt3 |
EEF1A lysine methyltransferase 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EEF1AKMT3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,320,845...70,328,452
Ensembl chr 7:70,321,077...70,328,148
|
|
G |
Efcab6 |
EF-hand calcium binding domain 6 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:124,758,376...124,948,428
Ensembl chr 7:124,758,378...124,929,025
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of EFHB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFHB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:47,988...120,800
Ensembl chr 9:47,724...120,799
|
|
G |
Efna1 |
ephrin A1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of EFNA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA p-Chloromercuribenzoic Acid results in increased expression of EGF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfl7 |
EGF-like-domain, multiple 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EGFL7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:4,034,759...4,044,280
Ensembl chr 3:4,034,921...4,043,936
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EGFR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eid2b |
EP300 interacting inhibitor of differentiation 2B |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:85,508,397...85,510,131
Ensembl chr 1:85,509,662...85,510,114
|
|
G |
Eid3 |
EP300 interacting inhibitor of differentiation 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EID3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:26,976,154...26,977,479
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EIF2AK4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF2AK4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:110,159,624...110,245,382
Ensembl chr 3:110,159,708...110,249,217
|
|
G |
Eif3e |
eukaryotic translation initiation factor 3 subunit E |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EIF3E mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:82,997,694...83,037,231
|
|
G |
Eif4e3 |
eukaryotic translation initiation factor 4E family member 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EIF4E3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:132,068,581...132,111,092
Ensembl chr 4:132,068,598...132,111,079
|
|
G |
Eno3 |
enolase 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ENO3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653
|
|
G |
Epcam |
epithelial cell adhesion molecule |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of EPCAM mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Epdr1 |
ependymin related 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of EPDR1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182
|
|
G |
Epha2 |
Eph receptor A2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:159,845,773...159,874,203
Ensembl chr 5:159,845,774...159,874,206
|
|
G |
Ephb1 |
Eph receptor B1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EPHB1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:110,376,954...110,813,193
Ensembl chr 8:110,376,954...110,813,000
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EPHB2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EPHX2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ERAP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
|
|
G |
Erich1 |
glutamate-rich 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ERICH1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:80,601,873...80,667,774
Ensembl chr16:80,601,973...80,667,781
|
|
G |
Erp27 |
endoplasmic reticulum protein 27 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ERP27 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:170,893,946...170,912,629
Ensembl chr 4:170,893,946...170,912,629
|
|
G |
Etaa1 |
ETAA1 activator of ATR kinase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ETAA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETAA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:102,290,655...102,293,674
Ensembl chr14:102,290,418...102,293,677
|
|
G |
Exoc7 |
exocyst complex component 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of EXOC7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:105,242,152...105,259,795
Ensembl chr10:105,242,152...105,259,795
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of F2RL2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533
|
|
G |
F5 |
coagulation factor V |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of F5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:82,479,997...82,535,540
Ensembl chr13:82,479,998...82,535,534
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FABP6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:29,191,621...29,196,593
Ensembl chr10:29,191,623...29,196,563
|
|
G |
Fam110c |
family with sequence similarity 110, member C |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FAM110C mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:49,968,473...49,974,730
Ensembl chr 6:49,968,473...49,974,728
|
|
G |
Fam124a |
family with sequence similarity 124 member A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FAM124A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:45,711,994...45,780,395
Ensembl chr15:45,712,821...45,780,405
|
|
G |
Fam126a |
family with sequence similarity 126, member A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FAM126A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM126A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:7,661,710...7,770,179
Ensembl chr 4:7,661,558...7,770,232
|
|
G |
Fam149a |
family with sequence similarity 149, member A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FAM149A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:50,049,816...50,105,962
Ensembl chr16:50,049,828...50,107,856
|
|
G |
Fam155a |
family with sequence similarity 155, member A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FAM155A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:85,528,126...86,053,447
|
|
G |
Fam169a |
family with sequence similarity 169, member A |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FAM169A mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:27,884,748...27,941,069
Ensembl chr 2:27,905,535...27,938,525
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FAM219A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM219A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:57,896,824...57,947,569
Ensembl chr 5:57,897,368...57,947,183
|
|
G |
Fank1 |
fibronectin type III and ankyrin repeat domains 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FANK1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371
|
|
G |
Farp2 |
FERM, ARH/RhoGEF and pleckstrin domain protein 2 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FARP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:100,660,366...100,767,940
Ensembl chr 9:100,660,394...100,767,940
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FAT3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644
|
|
G |
Fbf1 |
Fas binding factor 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FBF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:104,692,791...104,718,630
Ensembl chr10:104,692,755...104,718,621
|
|
G |
Fblim1 |
filamin binding LIM protein 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FBLIM1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:160,122,466...160,158,921
Ensembl chr 5:160,122,425...160,158,386
|
|
G |
Fbxl14 |
F-box and leucine-rich repeat protein 14 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FBXL14 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:151,986,890...151,990,706
|
|
G |
Fbxl17 |
F-box and leucine-rich repeat protein 17 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FBXL17 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:110,515,558...110,936,631
Ensembl chr 9:110,515,558...110,936,631
|
|
G |
Fbxo3 |
F-box protein 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FBXO3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:93,968,827...94,000,863
Ensembl chr 3:93,968,855...94,000,863
|
|
G |
Fbxo9 |
f-box protein 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FBXO9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FDFT1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FDFT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fech |
ferrochelatase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FECH mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FEZ1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fezf2 |
Fez family zinc finger 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FEZF2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:12,825,333...12,831,496
Ensembl chr15:12,827,707...12,831,496
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FGF8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FGF9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
|
|
G |
Fhod3 |
formin homology 2 domain containing 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FHOD3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:16,650,786...17,332,209
Ensembl chr18:16,650,806...17,332,210
|
|
G |
Filip1 |
filamin A interacting protein 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FILIP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FILIP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:87,257,312...87,453,432
Ensembl chr 8:87,256,264...87,419,564
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FJX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOS mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FOSL1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FOSL2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995
|
|
G |
Foxc1 |
forkhead box C1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FOXC1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:33,947,501...33,951,484
Ensembl chr17:33,947,506...33,951,484
|
|
G |
Frmd3 |
FERM domain containing 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FRMD3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:90,040,495...90,282,327
Ensembl chr 5:90,040,495...90,282,327
|
|
G |
Frzb |
frizzled-related protein |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FRZB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:67,635,604...67,668,772
Ensembl chr 3:67,635,607...67,668,772
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FTH1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FTL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Ftx |
FTX transcript, XIST regulator |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of FTX mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:74,440,265...74,484,164
|
|
G |
Fut8 |
fucosyltransferase 8 |
multiple interactions decreases expression decreases activity |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA; Fucose analog inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein] p-Chloromercuribenzoic Acid results in decreased expression of FUT8 mRNA |
CTD |
PMID:12770769 PMID:26272509 PMID:27188386 |
|
NCBI chr 6:100,305,957...100,537,208
Ensembl chr 6:100,337,226...100,537,224
|
|
G |
Fzd10 |
frizzled class receptor 10 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FZD10 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:31,757,407...31,760,604
Ensembl chr12:31,757,407...31,760,604
|
|
G |
Fzd2 |
frizzled class receptor 2 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of FZD2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of G3BP1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:40,812,858...40,846,252
Ensembl chr10:40,812,858...40,846,252
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gabra5 |
gamma-aminobutyric acid type A receptor subunit alpha 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GABRA5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:112,833,941...112,947,482
Ensembl chr 1:112,833,944...112,947,451
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GABRB3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GADD45A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gal |
galanin and GMAP prepropeptide |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GAL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:43,067,316...43,208,992
Ensembl chr10:43,067,299...43,210,427
|
|
G |
Galnt14 |
polypeptide N-acetylgalactosaminyltransferase 14 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GALNT14 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:24,770,308...24,985,711
Ensembl chr 6:24,770,317...24,985,716
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GALNT3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412
|
|
G |
Galp |
galanin-like peptide |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GALP mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:71,352,417...71,374,457
Ensembl chr 1:71,352,419...71,373,605
|
|
G |
Gars |
glycyl-tRNA synthetase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GARS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
|
|
G |
Gas1 |
growth arrest-specific 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GAS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gata2 |
GATA binding protein 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GATA2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GATA3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GCLC mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GCLM mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gcnt1 |
glucosaminyl (N-acetyl) transferase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GCNT1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:236,547,729...236,585,037
Ensembl chr 1:236,580,034...236,585,035
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GDF15 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gemin8 |
gem (nuclear organelle) associated protein 8 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GEMIN8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:29,806,605...29,825,439
Ensembl chr X:29,806,606...29,825,439
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GFRA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gins4 |
GINS complex subunit 4 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GINS4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GINS4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:73,584,412...73,596,808
Ensembl chr16:73,584,521...73,596,793
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GLIS3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360
|
|
G |
Gls |
glutaminase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GLS mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gng8 |
G protein subunit gamma 8 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GNG8 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GPAT3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:10,343,287...10,396,565
Ensembl chr14:10,343,282...10,395,047
|
|
G |
Gpm6b |
glycoprotein m6b |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GPM6B mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:29,604,607...29,751,174
Ensembl chr X:29,607,075...29,648,403
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GPNMB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr25 |
G protein-coupled receptor 25 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GPR25 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:53,135,815...53,139,180
Ensembl chr13:53,136,174...53,137,253
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GPX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gramd1c |
GRAM domain containing 1C |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GRAMD1C mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:61,609,370...61,659,355 NCBI chr11:62,580,983...62,634,961
Ensembl chr11:61,605,937...62,634,803
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GREM1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989
|
|
G |
Grhl3 |
grainyhead-like transcription factor 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GRHL3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:153,893,039...153,925,045
Ensembl chr 5:153,893,039...153,924,896
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GRIA3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:127,561,843...127,829,763
Ensembl chr X:127,562,660...127,829,753
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GRIN2A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Grm3 |
glutamate metabotropic receptor 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GRM3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:21,316,761...21,567,561
Ensembl chr 4:21,317,695...21,560,490
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of GSR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gtf2h1 |
general transcription factor IIH subunit 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GTF2H1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2H1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:102,849,618...102,877,939
Ensembl chr 1:102,849,889...102,877,944
|
|
G |
Gucy1a2 |
guanylate cyclase 1 soluble subunit alpha 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of GUCY1A2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:408,001...899,851
Ensembl chr 8:408,001...899,974
|
|
G |
H1f7 |
H1.7 linker histone |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of H1-7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:139,871,491...139,872,858
Ensembl chr 7:139,871,479...139,872,900
|
|
G |
Hacd1 |
3-hydroxyacyl-CoA dehydratase 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HACD1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:81,173,238...81,196,012
Ensembl chr17:81,173,713...81,187,739
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HAPLN1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:18,354,542...18,419,077
Ensembl chr 2:18,354,542...18,419,071
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HEG1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:70,234,248...70,322,966
Ensembl chr11:70,236,888...70,322,690
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HES1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HES5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188
|
|
G |
Hes7 |
hes family bHLH transcription factor 7 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HES7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:55,704,485...55,710,523
Ensembl chr10:55,707,164...55,709,687
|
|
G |
Hesx1 |
HESX homeobox 1 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HESX1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:2,616,538...2,636,708
Ensembl chr16:2,634,603...2,636,708
|
|
G |
Hif3a |
hypoxia inducible factor 3 subunit alpha |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:78,976,318...78,997,869
Ensembl chr 1:78,976,318...78,997,869
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA p-Chloromercuribenzoic Acid results in decreased expression of H2BC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:44,833,924...44,834,305
Ensembl chr17:44,833,924...44,834,305
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
increases activity |
EXP |
p-chloromercuribenzoic acid increases activity of purified Hmbs protein |
RGD |
PMID:3179323 |
RGD:2301707 |
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Hmgcll1 |
3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:83,069,837...83,204,778
Ensembl chr 8:83,070,545...83,205,441
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HMGCS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HMOX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HNRNPA2B1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPA2B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hnrnpl |
heterogeneous nuclear ribonucleoprotein L |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPL mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:86,994,090...87,006,776
Ensembl chr 1:86,996,093...87,006,776
|
|
G |
Hnrnpu |
heterogeneous nuclear ribonucleoprotein U |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HNRNPU mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:96,222,093...96,238,845
Ensembl chr13:96,225,912...96,238,572
|
|
G |
Hopx |
HOP homeobox |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HOPX mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOPX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:33,354,803...33,362,547
Ensembl chr14:33,354,807...33,362,551
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HPGD mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HPS3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:104,789,423...104,832,964
Ensembl chr 2:104,789,423...104,830,898
|
|
G |
Hrh3 |
histamine receptor H3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HRH3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HRK mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,008,879...44,029,211
|
|
G |
Hs3st3b1 |
heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HS3ST3B1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:50,369,097...50,402,584
Ensembl chr10:50,366,952...50,402,616
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HSD17B8 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HSPA12A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:279,946,809...280,104,366
Ensembl chr 1:279,946,811...280,015,358
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HSPA1L mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HSPA4L mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HSPH1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of HTATIP2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of HTRA1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513
|
|
G |
Ica1l |
islet cell autoantigen 1-like |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ICA1L mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:66,788,094...66,848,958
Ensembl chr 9:66,790,047...66,845,403
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ICAM1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ice2 |
interactor of little elongation complex ELL subunit 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ICE2 mRNA p-Chloromercuribenzoic Acid results in decreased expression of ICE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:75,625,147...75,666,959
Ensembl chr 8:75,625,174...75,666,866
|
|
G |
Icoslg |
inducible T-cell co-stimulator ligand |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ICOSLG mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICOSLG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:11,330,000...11,340,307
Ensembl chr20:11,329,992...11,340,296
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ID1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ier2 |
immediate early response 2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:25,774,146...25,775,670
Ensembl chr19:25,774,143...25,775,659
|
|
G |
Ier3 |
immediate early response 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of IER3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420
|
|
G |
Igdcc3 |
immunoglobulin superfamily, DCC subclass, member 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of IGDCC3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:70,630,546...70,685,882
Ensembl chr 8:70,630,767...70,684,115
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of IGFBP3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of IGFBP5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Igsf5 |
immunoglobulin superfamily, member 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of IGSF5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:36,736,580...36,779,614
Ensembl chr11:36,736,586...36,779,615
|
|
G |
Il1rapl1 |
interleukin 1 receptor accessory protein-like 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:55,439,388...57,004,865
Ensembl chr X:55,439,578...56,765,893
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of IL1RN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Ing3 |
inhibitor of growth family, member 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ING3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:49,017,235...49,044,450
Ensembl chr 4:49,017,311...49,042,990
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of INHBE mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of INPP5D mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of INSIG1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of IREB2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Isl2 |
ISL LIM homeobox 2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:60,117,565...60,122,716
Ensembl chr 8:60,117,729...60,122,211
|
|
G |
Itga4 |
integrin subunit alpha 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ITGA4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:66,178,745...66,265,547
Ensembl chr 3:66,193,059...66,263,960
|
|
G |
Itprid2 |
ITPR interacting domain containing 2 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ITPRID2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:66,593,767...66,631,143
Ensembl chr 3:66,593,934...66,631,723
|
|
G |
Jade1 |
jade family PHD finger 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of JADE1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:128,461,147...128,514,298
Ensembl chr 2:128,461,224...128,514,291
|
|
G |
Jazf1 |
JAZF zinc finger 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of JAZF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of JDP2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161
|
|
G |
Jph4 |
junctophilin 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of JPH4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:33,767,116...33,777,289
Ensembl chr15:33,768,595...33,775,109
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUNB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kat14 |
lysine acetyltransferase 14 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT14 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:138,508,899...138,549,437
Ensembl chr 3:138,504,214...138,549,437
|
|
G |
Kat6a |
lysine acetyltransferase 6A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KAT6A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:73,942,669...74,020,750
Ensembl chr16:73,943,455...74,023,005
|
|
G |
Katnbl1 |
katanin regulatory subunit B1 like 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KATNBL1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:103,511,653...103,513,498
Ensembl chr 3:103,866,144...103,905,936
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KCNK10 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:122,417,079...122,549,532
Ensembl chr 6:122,419,046...122,545,899
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KEAP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KIF1A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:100,171,851...100,253,626
Ensembl chr 9:100,171,772...100,253,609
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF5C mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407
|
|
G |
Kirrel2 |
kirre like nephrin family adhesion molecule 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KIRREL2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:88,909,829...88,921,154
Ensembl chr 1:88,910,415...88,920,291
|
|
G |
Klf5 |
Kruppel-like factor 5 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KLF5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Klf9 |
Kruppel-like factor 9 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KLF9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:240,908,483...240,933,198
Ensembl chr 1:240,908,483...240,933,198
|
|
G |
Klhdc8a |
kelch domain containing 8A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KLHDC8A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:49,074,644...49,082,729
Ensembl chr13:49,074,644...49,082,729
|
|
G |
Klhdc9 |
kelch domain containing 9 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KLHDC9 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:89,742,750...89,746,254
Ensembl chr13:89,742,750...89,745,835
|
|
G |
Klhl21 |
kelch-like family member 21 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:169,181,418...169,190,073
Ensembl chr 5:169,181,418...169,190,073
|
|
G |
Klhl29 |
kelch-like family member 29 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KLHL29 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL29 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:29,178,858...29,483,460
Ensembl chr 6:29,178,858...29,483,460
|
|
G |
Klhl5 |
kelch-like family member 5 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:44,805,213...44,867,075
Ensembl chr14:44,805,200...44,845,218
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KMT2A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:49,110,407...49,185,872
Ensembl chr 8:49,114,990...49,158,971
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of KRAS mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Krt18 |
keratin 18 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KRT18 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt8 |
keratin 8 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of KRT8 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Layn |
layilin |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LAYN mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:55,447,203...55,469,420
Ensembl chr 8:55,447,709...55,467,688
|
|
G |
Lfng |
LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LFNG mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:16,117,767...16,126,211
Ensembl chr12:16,118,634...16,126,953
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LHX2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446
|
|
G |
Lhx8 |
LIM homeobox 8 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LHX8 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:260,572,205...260,598,744
Ensembl chr 2:260,574,190...260,596,777
|
|
G |
Lifr |
LIF receptor subunit alpha |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LIFR mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
|
|
G |
Lix1 |
limb and CNS expressed 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LIX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:59,156,021...59,212,878
Ensembl chr 1:59,156,251...59,214,452
|
|
G |
Lman1 |
lectin, mannose-binding, 1 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LMAN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:61,683,377...61,707,344
Ensembl chr18:61,685,117...61,707,317
|
|
G |
Lmf1 |
lipase maturation factor 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LMF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:14,945,185...15,031,855
Ensembl chr10:14,945,265...15,031,942
|
|
G |
Lmln |
leishmanolysin like peptidase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LMLN mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMLN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:70,895,141...70,963,121
Ensembl chr11:70,897,052...70,961,358
|
|
G |
Lmo1 |
LIM domain only 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LMO1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:173,728,183...173,764,288
Ensembl chr 1:173,728,184...173,764,250
|
|
G |
Lmo3 |
LIM domain only 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LMO3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:172,942,023...173,005,630
Ensembl chr 4:172,942,020...173,005,634
|
|
G |
Lmo7 |
LIM domain 7 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LMO7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:86,242,911...86,458,512
Ensembl chr15:86,243,148...86,457,739
|
|
G |
Lnx1 |
ligand of numb-protein X 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LNX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:36,047,136...36,149,740
Ensembl chr14:36,047,144...36,149,740
|
|
G |
LOC100910258 |
zinc finger protein 599-like |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ZNF599 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF599 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:89,672,308...89,686,143
|
|
G |
LOC498122 |
similar to CG15908-PA |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of C22ORF39 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:86,299,210...86,303,453
Ensembl chr11:86,299,210...86,303,453
|
|
G |
LOC686035 |
similar to heat shock 70kDa protein 6 (HSP70B) |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:89,408,703...89,411,500
|
|
G |
LOC689959 |
hypothetical protein LOC689959 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:55,164,736...55,174,613
Ensembl chr 8:55,164,736...55,171,718
|
|
G |
LOC691113 |
hypothetical protein LOC691113 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of C2ORF68 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:100,208,612...100,215,824
Ensembl chr 4:100,209,951...100,212,122
|
|
G |
Lonrf3 |
LON peptidase N-terminal domain and ring finger 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LONRF3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:122,937,987...122,973,289
Ensembl chr X:122,938,009...122,973,321
|
|
G |
Lrrc34 |
leucine rich repeat containing 34 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LRRC34 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:116,370,013...116,391,964
Ensembl chr 2:116,372,519...116,391,959
|
|
G |
Lrrc3b |
leucine rich repeat containing 3B |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LRRC3B mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:11,221,161...11,299,563
Ensembl chr15:11,298,478...11,299,257
|
|
G |
Lrrc55 |
leucine rich repeat containing 55 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LRRC55 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:72,589,840...72,605,089
Ensembl chr 3:72,589,842...72,602,548
|
|
G |
Lrrtm4 |
leucine rich repeat transmembrane neuronal 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of LRRTM4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:110,699,577...111,497,643
Ensembl chr 4:110,699,557...111,497,643
|
|
G |
Lurap1 |
leucine rich adaptor protein 1 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of LURAP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:134,991,997...135,001,720
Ensembl chr 5:134,991,997...135,001,720
|
|
G |
Lztfl1 |
leucine zipper transcription factor-like 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LZTFL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:132,774,393...132,790,922
Ensembl chr 8:132,775,587...132,790,839
|
|
G |
Mab21l2 |
mab-21 like 2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:185,849,749...185,852,833
Ensembl chr 2:185,850,232...185,852,759
|
|
G |
Macc1 |
MET transcriptional regulator MACC1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MACC1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:147,315,232...147,392,530
Ensembl chr 6:147,315,328...147,394,269
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MACROH2A1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MAF mRNA |
CTD |
PMID:26272509 |
|
NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
|
|
G |
Mafg |
MAF bZIP transcription factor G |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MAFG mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MAN1A1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:35,257,688...35,450,132
Ensembl chr20:35,257,985...35,450,513
|
|
G |
Man1c1 |
mannosidase, alpha, class 1C, member 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MAN1C1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:152,775,031...152,920,130
Ensembl chr 5:152,774,855...152,920,343
|
|
G |
Map1a |
microtubule-associated protein 1A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MAP1A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MAP2K6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:91,303,428...91,353,601
Ensembl chr10:91,303,428...91,353,601
|
|
G |
Map6 |
microtubule-associated protein 6 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MAP6 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093
|
|
G |
Map7 |
microtubule-associated protein 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MAP7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:15,620,665...15,748,203
Ensembl chr 1:15,620,653...15,748,203
|
|
G |
Marchf1 |
membrane associated ring-CH-type finger 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MARCHF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARCHF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:24,998,709...25,856,327
Ensembl chr16:25,001,666...25,192,675
|
|
G |
Mars1 |
methionyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARS1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:70,585,011...70,602,425
Ensembl chr 7:70,585,013...70,602,310
|
|
G |
Marveld3 |
MARVEL domain containing 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MARVELD3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:41,710,076...41,724,923
Ensembl chr19:41,710,102...41,724,923
|
|
G |
Matk |
megakaryocyte-associated tyrosine kinase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MATK mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:11,325,246...11,334,311
Ensembl chr 7:11,325,254...11,330,278
|
|
G |
Mcc |
MCC regulator of WNT signaling pathway |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MCC mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:35,683,185...35,817,117 NCBI chr 1:12,006,663...12,128,849
Ensembl chr 1:12,006,660...12,128,845 Ensembl chr18:12,006,660...12,128,845
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MCM7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
|
|
G |
Mcoln3 |
mucolipin TRP cation channel 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MCOLN3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:251,930,532...252,007,722
Ensembl chr 2:251,983,339...252,007,560
|
|
G |
Mctp1 |
multiple C2 and transmembrane domain containing 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MCTP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:3,400,883...4,089,949
Ensembl chr 2:3,400,977...4,088,989
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MDM2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Me1 |
malic enzyme 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of ME1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Me3 |
malic enzyme 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of ME3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,861,535...154,058,608
Ensembl chr 1:153,861,569...154,056,654
|
|
G |
Med24 |
mediator complex subunit 24 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MED24 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:86,620,166...86,658,014
Ensembl chr10:86,620,160...86,645,529
|
|
G |
Meiob |
meiosis specific with OB-fold |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MEIOB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:14,174,645...14,206,026
Ensembl chr10:14,174,732...14,206,025
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MEOX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491
|
|
G |
Mettl7b |
methyltransferase like 7B |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of METTL7B mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:3,383,876...3,386,522
Ensembl chr 7:3,383,879...3,386,522
|
|
G |
Mfap3l |
microfibril associated protein 3 like |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MFAP3L mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:32,734,059...32,777,091
Ensembl chr16:32,738,265...32,753,278
|
|
G |
Mfng |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MFNG mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:119,978,981...119,996,824
Ensembl chr 7:119,978,983...119,996,824
|
|
G |
Miat |
myocardial infarction associated transcript |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MIAT mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:50,447,251...50,461,859
|
|
G |
Mical3 |
microtubule associated monooxygenase, calponin and LIM domain containing 3 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MICAL3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:153,484,876...153,631,986
Ensembl chr 4:153,484,876...153,593,773
|
|
G |
Mier3 |
MIER family member 3 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MIER3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:43,266,301...43,295,175
Ensembl chr 2:43,266,739...43,294,889
|
|
G |
Mif4gd |
MIF4G domain containing |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MIF4GD mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:104,159,170...104,164,166
Ensembl chr10:104,159,173...104,163,634
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mkln1 |
muskelin 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MKLN1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:58,693,384...58,817,924
Ensembl chr 4:58,693,384...58,817,691
|
|
G |
Mlxip |
MLX interacting protein |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MLXIP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:38,567,438...38,638,952
Ensembl chr12:38,567,247...38,638,536
|
|
G |
Mmab |
metabolism of cobalamin associated B |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MMAB mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:47,920,712...47,935,438
Ensembl chr12:47,920,743...47,935,525
|
|
G |
Mnx1 |
motor neuron and pancreas homeobox 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MNX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:2,376,350...2,381,308
Ensembl chr 4:2,376,958...2,381,271
|
|
G |
Mphosph8 |
M-phase phosphoprotein 8 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPHOSPH8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:36,918,843...36,946,712
Ensembl chr15:36,918,843...36,946,708
|
|
G |
Mpi |
mannose phosphate isomerase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MPI mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:62,324,176...62,332,080
Ensembl chr 8:62,324,092...62,332,115
|
|
G |
Mpp7 |
membrane palmitoylated protein 7 |
decreases expression |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MPP7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:60,057,077...60,250,303
Ensembl chr17:60,059,949...60,250,352
|
|
G |
Mrps14 |
mitochondrial ribosomal protein S14 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MRPS14 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPS14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:77,940,454...77,946,201
Ensembl chr13:77,940,454...77,946,201
|
|
G |
Msrb3 |
methionine sulfoxide reductase B3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MSRB3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:62,850,506...62,972,487
Ensembl chr 7:62,850,515...62,972,084
|
|
G |
Msx1 |
msh homeobox 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MSX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:77,712,262...77,716,061
Ensembl chr14:77,712,240...77,716,059
|
|
G |
Msx2 |
msh homeobox 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MSX2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:11,683,862...11,689,527
Ensembl chr17:11,683,862...11,689,527
|
|
G |
Mt2A |
metallothionein 2A |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MT2A mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtss1 |
MTSS I-BAR domain containing 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MTSS1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:98,820,799...98,960,878
Ensembl chr 7:98,820,812...98,960,837
|
|
G |
Muc15 |
mucin 15, cell surface associated |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MUC15 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:101,895,363...101,912,979
Ensembl chr 3:101,899,068...101,912,919
|
|
G |
Mxd1 |
max dimerization protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MXD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:118,451,752...118,472,150
Ensembl chr 4:118,449,882...118,472,179
|
|
G |
Mycl |
MYCL proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MYCL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:140,691,947...140,698,837
Ensembl chr 5:140,692,779...140,698,609
|
|
G |
Mylip |
myosin regulatory light chain interacting protein |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MYLIP mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:19,682,040...19,703,681
Ensembl chr17:19,682,040...19,703,681
|
|
G |
Mylk |
myosin light chain kinase |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of MYLK mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Myo10 |
myosin X |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:77,868,398...78,072,443
Ensembl chr 2:77,868,412...78,071,309
|
|
G |
Myof |
myoferlin |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of MYOF mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
|
|
G |
N4bp2l2 |
NEDD4 binding protein 2-like 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of N4BP2L2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:627,128...650,604
Ensembl chr12:628,488...650,376
|
|
G |
Nabp1 |
nucleic acid binding protein 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NABP1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:55,049,893...55,057,784
Ensembl chr 9:55,050,203...55,057,658
|
|
G |
Nadk2 |
NAD kinase 2, mitochondrial |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NADK2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:58,462,588...58,504,735
Ensembl chr 2:58,462,588...58,504,728
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NAP1L5 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAP1L5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:89,149,314...89,152,511
Ensembl chr 4:89,149,317...89,151,184
|
|
G |
Nat1 |
N-acetyltransferase 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NAT1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
|
|
G |
Natd1 |
N-acetyltransferase domain containing 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NATD1 mRNA p-Chloromercuribenzoic Acid results in decreased expression of NATD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:47,154,443...47,164,622
Ensembl chr10:47,157,481...47,164,596
|
|
G |
Ncald |
neurocalcin delta |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NCALD mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:76,199,305...76,632,847
Ensembl chr 7:76,199,306...76,488,216
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NCAM1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Ncan |
neurocan |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NCAN mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:21,050,243...21,076,707
Ensembl chr16:21,050,243...21,076,707
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NCOA7 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:29,225,727...29,386,642
Ensembl chr 1:29,225,707...29,385,199
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NDP mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:6,791,090...6,815,586
Ensembl chr X:6,791,136...6,815,583 Ensembl chr X:6,791,136...6,815,583
|
|
G |
Ndufb1 |
NADH:ubiquinone oxidoreductase subunit B1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NDUFB1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:125,861,219...125,870,231
|
|
G |
Nebl |
nebulette |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NEBL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEBL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:84,141,014...84,247,038
Ensembl chr17:84,140,489...84,488,601
|
|
G |
Nectin4 |
nectin cell adhesion molecule 4 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NECTIN4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:89,755,665...89,774,185
Ensembl chr13:89,755,845...89,774,378
|
|
G |
Nefm |
neurofilament medium |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NEFM mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604
|
|
G |
Nell2 |
neural EGFL like 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NELL2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:136,526,497...136,853,820
Ensembl chr 7:136,526,496...136,853,957
|
|
G |
Nexmif |
neurite extension and migration factor |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NEXMIF mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:74,943,440...75,053,559
Ensembl chr X:74,945,082...74,968,405
|
|
G |
Nf1 |
neurofibromin 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NF1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
|
|
G |
Nfasc |
neurofascin |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NFASC mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:49,335,407...49,522,474
Ensembl chr13:49,335,408...49,522,415
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NFE2L2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NFKBIZ mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFKBIZ mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
|
|
G |
Nhlh2 |
nescient helix loop helix 2 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NHLH2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:204,427,577...204,432,946
Ensembl chr 2:204,427,608...204,432,946
|
|
G |
Nhs |
NHS actin remodeling regulator |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NHS mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:34,312,102...34,675,912
Ensembl chr X:34,623,405...34,673,742
|
|
G |
Nkain3 |
Sodium/potassium transporting ATPase interacting 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA p-Chloromercuribenzoic Acid results in decreased expression of NKAIN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:34,133,596...34,813,668
Ensembl chr 5:34,174,411...34,813,116
|
|
G |
Nmrk1 |
nicotinamide riboside kinase 1 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NMRK1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:234,721,992...234,749,452
Ensembl chr 1:234,721,974...234,749,447
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ZBTB47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACADSB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDOC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD18A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD26 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATG10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AURKA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAG5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLOC1S5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BTN3A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C4ORF47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP83 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLUAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUZD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCL6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX58 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3OS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EBF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF2AK4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETAA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM126A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FDFT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FILIP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GEMIN8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLUD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2H1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H3C10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOPX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HPS3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ICE2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL29 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00648 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00664 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00960 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01006 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01138 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMLN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LZTFL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARCHF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED24 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR210HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKLN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPS14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAP1L5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NATD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP160 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP62CL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OBSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ODF3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSCP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPLN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARP16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAXIP1-DT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCBP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH18 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDCD4-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDZD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PFKFB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF20L1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKNOX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU4F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPIL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R16A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R1C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRIMA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKCB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PSMB8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTRH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PXK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PYGO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB40B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RABGAP1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAI2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REPS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RET mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFLNB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIPPLY3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RND2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF125 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RORB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSBN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUNDC3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMD13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMHD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEC24B-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOW mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPTIN6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEZ6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIDA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A43 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC2A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC39A10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC3A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC4A8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLITRK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMARCE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMIM14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMKR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAP23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPIN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPIRE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SQLE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SREBF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSX2IP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STAMBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUV39H2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAF9B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCEAL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCF25 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEKT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TFDP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TINCR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TKFC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM107 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM108 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM231 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNFRSF19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOB1-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOLLIP-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAPPC11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRMT1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTC30A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTYH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TWIST2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2J1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ULK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UPK1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VCAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WIBG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WIF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WSCD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XPNPEP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZDHHC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFPM2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZHX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF174 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF214 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF382 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF599 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF704 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN12 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN31 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD36B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF40 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARMH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATXN2L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CABYR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42BPA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COPG2IT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTCFL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLGAP1-AS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFHB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM219A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GINS4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GOLGA8H mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GUSBP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPA2B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICOSLG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUNB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF25-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF5C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC-PINT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00304 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01234 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIAT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR570HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPHOSPH8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1E mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1F mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1G mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1H mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1M mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MXD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEBL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFKBIZ mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLRP7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALLD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PANX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDHB7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PERP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMAIP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R15A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSMA5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSMD11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSME4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSPH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PVT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RDH12 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REV3L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMD4A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCARNA17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN8A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERTAD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFXN5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHTN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC10A4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC13A4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC22A15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC6A16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQSTM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRXN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STK17A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TEX19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFE3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THUMPD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM268 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM37 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPTE2P6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TREX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM73 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRO mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSGA10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UCHL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNKL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEGFA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWTR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XIST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZDHHC13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
|
|
G |
Nol3 |
nucleolar protein 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NOL3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:37,232,567...37,236,668
Ensembl chr19:37,235,001...37,236,649
|
|
G |
Nol4 |
nucleolar protein 4 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:13,658,260...14,016,713
Ensembl chr18:13,658,271...14,016,713
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NOS2 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nphp4 |
nephrocystin 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NPHP4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:169,647,581...169,744,662
Ensembl chr 5:169,659,188...169,744,660
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NPPB mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NPTX1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:108,682,637...108,691,592
Ensembl chr10:108,682,638...108,691,367
|
|
G |
Npy2r |
neuropeptide Y receptor Y2 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NPY2R mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:181,528,949...181,538,145
Ensembl chr 2:181,530,832...181,531,978
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA p-Chloromercuribenzoic Acid results in increased expression of NQO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NR2F1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
multiple interactions |
ISO |
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:131,447,671...131,465,749
Ensembl chr 1:131,448,447...131,460,473
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NRIP3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:174,385,424...174,411,141
Ensembl chr 1:174,385,424...174,411,141
|
|
G |
Nrxn3 |
neurexin 3 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NRXN3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:112,133,204...114,069,589
Ensembl chr 6:112,133,204...114,067,564
|
|
G |
Nsl1 |
NSL1 component of MIS12 kinetochore complex |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NSL1 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:109,669,646...109,697,849
Ensembl chr13:109,669,680...109,696,918
|
|
G |
Nsun6 |
NOP2/Sun RNA methyltransferase 6 |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NSUN6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr17:82,020,316...82,060,533
Ensembl chr17:82,022,490...82,060,123
|
|
G |
Ntn4 |
netrin 4 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NTN4 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:34,533,543...34,649,330
Ensembl chr 7:34,533,543...34,649,481
|
|
G |
Nup160 |
nucleoporin 160 |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NUP160 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP160 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:79,496,239...79,562,163
Ensembl chr 3:79,498,179...79,551,128
|
|
G |
Nup62cl |
nucleoporin 62 C-terminal like |
decreases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in decreased expression of NUP62CL mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP62CL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:111,333,274...111,390,023
Ensembl chr X:111,334,252...111,365,849
|
|
G |
Nutm2f |
NUT family member 2F |
increases expression |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NUTM2B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:15,022,052...15,031,768
Ensembl chr17:15,022,951...15,030,364
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression multiple interactions |
ISO |
p-Chloromercuribenzoic Acid results in increased expression of NXPE3 mRNA [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:47,188,332...47,238,372
Ensembl chr11:47,188,495...47,238,372
|